Sfoglia per AUTORE
RIA R
Collezione AO Ordine Mauriziano

  

Items : 5

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. in Journal of hematology & oncology / J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Ria R; Vacca A; Dammacco F; Boccadoro M; Petrucci MT; Musto P; Montefusco V; Rizzo M; Gottardi D; Falcone AP; Grasso M; Leonardi G; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Patriarca F; Martino E; Larocca A; Offidani M; De Paoli L; Bringhen S; Palumbo A; Omedè P; Terragna C; Giuliani N; Morabito F; Saltarella I; et alii...

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib- melphalanprednisone (VMP) in untreated multiple myeloma patients with renal impairment in Blood

2011
AO Ordine Mauriziano

Morabito F; Gentile M; Mazzone C; Rossi D; Di Raimondo F; Bringhen S; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci MT; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Montefusco V; Musto P; Cascavilla N; Majolino I; Musolino C; Cavo M; Boccadoro M; Palumbo A;

VMPT (bortezomib, melphalan, prednisone and thalidomide) followed by maintenance with bortezomib-thalidomide (VT) is active and well tolerated in newly diagnosed patients with multiple myeloma (MM) with moderate renal impairment (RI) ineligible for autologous stem cell transplantation: Results from a cohort analysis of a phase III randomized controlled trial in Haematologica

2011
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Morabito F; Gentile M; Mazzone C; Rossi D; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci M; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Musto P; Liberati A; Cascavilla N; Cangialosi C; Majolino I; Musolino C; Zambello R; Di Raimondo F; Cavo M; Boccadoro M; Palumbo A;

Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients in Blood

2009
AO Ordine Mauriziano
AOU Città della Salute di Torino

Palumbo A; Bringhen S; Rossi D; Ria R; Offidani M; Patriarca F; Nozzoli C; Levi A; Guglielmelli T; Benevolo G; Callea V; Olivero B; Morabito F; Grasso M; Marasca R; Rizzo M; Pia Falcone A; Gottardi D; Montefusco V; Musolino C; Zambello R; Cangialosi C; Pietrantuono G; Magarotto V; Petrucci MT; Musto P; Ciccone G; Di Raimondo F; Gaidano G; et alii...